White Pine Capital LLC purchased a new stake in shares of Danaher Corporation (NYSE:DHR – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,919 shares of the conglomerate’s stock, valued at approximately $647,000.
Several other institutional investors and hedge funds have also modified their holdings of DHR. Bessemer Group Inc. lifted its holdings in Danaher by 2.5% in the 3rd quarter. Bessemer Group Inc. now owns 37,406 shares of the conglomerate’s stock worth $8,286,000 after purchasing an additional 917 shares during the last quarter. Phoenix Financial Ltd. grew its holdings in Danaher by 54.7% during the third quarter. Phoenix Financial Ltd. now owns 10,641 shares of the conglomerate’s stock valued at $2,359,000 after purchasing an additional 3,761 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its holdings in Danaher by 2,444,444.4% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 220,009 shares of the conglomerate’s stock valued at $48,831,000 after purchasing an additional 220,000 shares during the last quarter. Danske Bank A S raised its position in shares of Danaher by 16.6% in the third quarter. Danske Bank A S now owns 379,684 shares of the conglomerate’s stock valued at $84,119,000 after purchasing an additional 54,035 shares during the period. Finally, Cornerstone Advisory LLC raised its position in shares of Danaher by 9.3% in the third quarter. Cornerstone Advisory LLC now owns 1,960 shares of the conglomerate’s stock valued at $434,000 after purchasing an additional 166 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.
Analyst Ratings Changes
A number of analysts have recently weighed in on the stock. Deutsche Bank restated a “buy” rating and issued a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. TD Cowen raised their target price on shares of Danaher from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Royal Bank Of Canada raised their target price on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research note on Monday, October 5th. JPMorgan Chase & Co. lifted their target price on shares of Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a report on Thursday, October 22nd. Finally, Wells Fargo & Company cut their target price on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 22nd. Eighteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $242.91.
Read Our Latest Research Report on Danaher
Danaher Stock Performance
NYSE DHR opened at $230.00 on Tuesday. The company’s fifty day moving average is $223.01 and its two-hundred day moving average is $201.55. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.63 and a quick ratio of 1.29. The firm has a market capitalization of $161.81 billion, a price-to-earnings ratio of 37.64, a P/E/G ratio of 2.92 and a beta of 0.76.
Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.19. The firm had revenue of $6.55 billion for the quarter, compared to analyst estimates of $6.56 billion. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.89 earnings per share. Equities research analysts forecast that Danaher Corporation will post 8.59 EPS for the current year.
Danaher Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is presently 26.19%.
Insider Buying and Selling
In related news, EVP Gregory M. Milosevich sold 2,100 shares of the firm’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $230.62, for a total value of $484,302.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company’s stock, valued at $5,158,277.54. This trade represents a 8.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Christopher Bouda sold 7,598 shares of the firm’s stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $234.56, for a total value of $1,782,186.88. Following the completion of the transaction, the chief accounting officer directly owned 9,107 shares of the company’s stock, valued at approximately $2,136,137.92. This trade represents a 45.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 10.80% of the company’s stock.
About Danaher
Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.
See Also
- Five stocks we like better than Danaher
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
